Dendrite Hosting Analyst Day; February 16 Presentations to Include Revenue and Other Outlook for 2006

During the event, John Bailye, Chairman and Chief ExecutiveOfficer, Joe Ripp, President and COO, and Jeff Bairstow, ExecutiveVice President and CFO, will discuss the Company's strategy andvision, and revenue and other outlook for 2006. Further insight intothe Company's 2005 results will also be provided. In addition, membersof Dendrite's management team will present overviews of the Company'ssolutions and share information on market trends and opportunities.

A link to a live simulcast of the event and a replay will beavailable at http://www.shareholder.com/drte/medialist.cfm. Investorsmay also call (800) 247-9979 (United States) or (973) 409-9254(international), conference ID number 6925617, to listen live to thepresentations. An audio replay of the presentations will be availablethrough March 9, 2006 by calling (877) 519-4474 (United States) or(973) 341-3080; conference ID number 6925617. The links and call-indetails can also be found at www.dendrite.com in the Investors'Highlights section.

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) enablessales, marketing, clinical and compliance solutions for the globalpharmaceutical industry. The company has clients in more than 50countries and includes the world's top 20 pharmaceutical companies.For more information, please visit www.dendrite.com.

Note: Dendrite is a registered trademark of DendriteInternational, Inc.

The noticed event may contain forward-looking statements that maybe identified by such forward-looking terminology as "expect,""believe," "anticipate," "will," "intend," "plan," "target,""outlook," "guidance," and similar statements or variations. Suchforward-looking statements are based on our current expectations,estimates, assumptions and projections and involve significant risksand uncertainties, including risks which may result from ourdependence on the pharmaceutical industry; fluctuations in quarterlyrevenues due to lengthy sales and implementation cycles for certain ofour solutions; our fixed expenses in relation to fluctuating revenuesand variations in customers' budget cycles; dependence on certainmajor customers; changes in demand for our products and servicesattributable to any weakness experienced in the economy or mergers,acquisitions and consolidations in the pharmaceutical industry;successful and timely development and introduction of new products andversions; rapid technological changes; increased competition;international operations; integrating the entities we acquire; ourability to effectively manage our growth; the protection of ourproprietary technology; our ability to compete in the Internet-relatedproducts and services market; the continued demand forInternet-related products and services; the ability of our third partyvendors to respond to technological change; our ability to maintainour relationships with third-party vendors; less favorable thananticipated results from strategic relationships; dependence of datasolutions on strategic relationships; events which may affect the U.S.and world economies; and catastrophic events which could negativelyaffect our information technology infrastructure. Other importantfactors that should be reviewed and carefully considered are includedin the company's 10-K, 10-Qs, and other reports filed with the SEC.Actual results may differ materially. The company assumes noobligation for updating any such forward-looking statements to reflectactual results, changes in assumptions or other changes affecting suchforward-looking statements.